이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Understanding Brain Reward Responses in Individuals With Major Depressive Disorder

2014년 4월 16일 업데이트: Diego A. Pizzagalli, Mclean Hospital

Neuroimaging Studies of Reward Processing in Depression

This study will examine brain responses associated with reinforcement and reward tasks in individuals with major depressive disorder (MDD).

연구 개요

상태

완전한

정황

상세 설명

Major depressive disorder (MDD) is a severe form of depression that can significantly interfere with an individual's thoughts, behavior, mood, and physical health. People who suffer from MDD may experience anhedonia, or the inability to gain pleasure from normally pleasurable experiences. Such individuals do not respond to motivational rewards in the same way as do individuals who are not depressed. Anhedonia has been recognized as a core symptom of depression and it is not always remedied with antidepressant medication. Abnormal brain activity and processing may be the underlying cause of depression and specifically anhedonia. A better understanding of the brain mechanisms of depression may lead to the development of new effective medications or psychological treatments.

Event-related potential (ERP), which measures electrical activity in the brain, and functional magnetic resonance imaging (fMRI), which uses scanned images to illustrate changes in brain activity, are two techniques that can identify abnormal areas of brain processing. The purpose of this study is to use ERP and fMRI to compare brain activity that is related to reward processing in individuals with MDD versus individuals without MDD.

This study will consist of 3 study visits; visits will be scheduled as close together as possible. At the first study visit, potential participants will be assessed with the SCID (Structured Clinical Interview for DSM-IV), which will identify individuals with the diagnostic criteria for MDD. A control group of non-depressed individuals will also be enrolled in the study. During the second and third study visits, participants will take part in a monetary reinforcement reward task followed by a signal detection reward task. Brain activity of all participants will be monitored during both tasks. During the second study visit, ERP will be used; during the third study visit, fMRI will be used. Demographic information will also be collected, and participants will complete several standardized questionnaires to assess mood. Some participants will be asked to return after eight weeks to complete the fMRI and EEG sessions again. Those who do complete all five sessions will be awarded a bonus.

연구 유형

관찰

등록 (실제)

87

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Massachusetts
      • Boston, Massachusetts, 미국, 02114
        • The Depression Clinical and Research Program, Massachusetts General Hospital
      • Cambridge, Massachusetts, 미국, 02138
        • Affective Neuroscience Laboratory, Department of Psychology, Harvard University
      • Charlestown, Massachusetts, 미국, 02129
        • Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

연구 대상 성별

모두

샘플링 방법

확률 샘플

연구 인구

Control participants, Participants with MDD

설명

Overall Inclusion Criteria:

  • Right-handed
  • Agrees to use an effective form of contraception throughout the study

Inclusion Criteria for Depressed Participants:

  • Meets overall inclusion criteria
  • Meets DSM-IV diagnosis criteria for major depressive disorder
  • Score of at least 16 on the 21-item HAM-D scale

Overall Exclusion Criteria:

  • Left-handed or ambidextrous
  • Claustrophobic
  • Neurological or medical illness (e.g., attention deficit hyperactivity disorder, head injury, loss of consciousness, seizures)
  • Pregnant

Exclusion Criteria for Depressed Participants:

  • Meets any of the overall exclusion criteria
  • Has been treated with electroconvulsive therapy within 6 months of study entry
  • Has taken any benzodiazepine medications for at least 2 weeks prior to study entry and discontinued use of the medication for reasons other than participating in the study
  • Has taken any dopaminergic medications (including methylphenidate) or neuroleptics for at least 6 months prior to study entry and discontinued use of the medication for reasons other than participating in the study
  • Has taken any fluoxetine medications for at least 6 weeks prior to study entry and discontinued use of the medication for reasons other than participating in the study
  • Has taken any medications that may have antidepressant properties (including some herbal supplements) within 2 weeks of study entry
  • Has taken any medications that may affect blood flow (including some blood pressure medications) within 2 weeks of study entry
  • Current or past history of MDD with psychotic features
  • Meets DSM-IV diagnosis criteria for organic mental disorder; substance use disorder (within 1 year of study entry); lifetime substance dependence; schizophrenia; delusional disorder; bipolar disorder; post-traumatic stress disorder; eating disorder; acute bereavement; severe borderline or antisocial personality disorder; or any psychotic disorder not otherwise specified
  • Current primary diagnosis of panic disorder, social phobia, generalized anxiety disorder, obsessive-compulsive disorder, or somatoform disorder

Exclusion Criteria for Control Participants

  • Meets any of the overall exclusion criteria
  • Diagnosed with any medical or neurological illness
  • Diagnosed with any current or past psychiatric illness, as assessed by the SCID-I, including substance abuse or dependence (e.g., alcohol)
  • Has taken any medications that may have antidepressant properties (including some herbal supplements) within 2 weeks of study entry
  • Has taken any psychotropic medications within 2 weeks of study entry
  • Has taken any medications that may affect blood flow (including some blood pressure medications) within 2 weeks of study entry

Exclusion Criteria for fMRI Studies:

  • Meets any of the overall exclusion criteria
  • Fails to meet safety standards for fMRI
  • Current back problems
  • Has strongly corrected vision, but does not wear contact lenses
  • Weighs more than 250 pounds or exceeds the limit of height-to-weight ratio for a comfortable fit in the scanner
  • Pregnant
  • Current alcohol or substance abuse
  • At risk for suicide or homicide

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

코호트 및 개입

그룹/코호트
1
Control participants
2
Participants with MDD

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Performance on Monetary Incentive Delay task
기간: Given once during the second session for half an hour, and once during the third session for half an hour
This task features balanced incentive delivery and analytic strategies designed to identify activity specific to anticipation or consumption of incentives.
Given once during the second session for half an hour, and once during the third session for half an hour
Signal detection reward task
기간: Given once during the second session for fifteen minutes, and once during the third session for fifteen minutes
This reward task provides an objective assessment of hedonic capacity. Due to the probabilistic nature of the task, participants cannot infer which stimulus is more advantageous based on the outcome of single trials but need to integrate reinforcement history over time to optimize behavior.
Given once during the second session for fifteen minutes, and once during the third session for fifteen minutes

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Diego A. Pizzagalli, PhD, Harvard University

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2005년 4월 1일

기본 완료 (실제)

2009년 4월 1일

연구 완료 (실제)

2009년 4월 1일

연구 등록 날짜

최초 제출

2005년 9월 14일

QC 기준을 충족하는 최초 제출

2005년 9월 14일

처음 게시됨 (추정)

2005년 9월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (추정)

2014년 4월 21일

QC 기준을 충족하는 마지막 업데이트 제출

2014년 4월 16일

마지막으로 확인됨

2014년 4월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • R01MH068376 (미국 NIH 보조금/계약)
  • DATR A3-NSS (Indiana University)

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

3
구독하다